Sorbitol
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Sorbitol
- Sorbitol: From an Unspecified Original Indication to Exercise-Induced Malignant Hyperthermia
Sorbitol: From an Unspecified Original Indication to Exercise-Induced Malignant Hyperthermia
One-Sentence Summary
Sorbitol is a sugar alcohol used as an osmotic agent, laxative and excipient. No original indication is recorded in the data compiled for this report. The TxGNN model predicts it may be effective for exercise-induced malignant hyperthermia, but there are no clinical trials and no publications supporting this direction. The prediction rests on a computational score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the data compiled for this report |
| Predicted New Indication | Exercise-induced malignant hyperthermia |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L5 |
| UK Market Status | Marketed |
| Number of Marketing Authorisations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Sorbitol is generally known as an osmotic agent, laxative and pharmaceutical excipient. No efficacy in a defined original indication could be confirmed from the data compiled.
Malignant hyperthermia is a disorder of skeletal muscle calcium regulation, typically linked to RYR1 variants and triggered by volatile anaesthetics or succinylcholine. No plausible direct link between sorbitol and ryanodine receptor function or calcium handling is evident. The high score (0.994) may reflect proximity within the knowledge graph, for example through shared osmotic, fluid-balance or excipient-related nodes, rather than a true therapeutic effect. The prediction needs mechanistic validation before it can be taken forward.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
| Marketing Authorisation Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 1203050A0AAAKAK | Mucin/Xylitol/Sorbitol Lozenge 65/59/55.5 mg | Not specified | Not specified |
The single authorisation is a combination lozenge product (mucin, xylitol and sorbitol). The listed number does not follow the usual MHRA PL format and should be verified against the MHRA register.
Safety Considerations
- Knowledge-graph contraindication signal: The TxGNN knowledge graph (not label text) links sorbitol to a contraindication in active peptic ulcer disease.
- Drug Interactions (2 found):
- Tolevamer: Major
- Lamivudine: Moderate
Please refer to the SmPC and BNF for full safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score, with no clinical trials, no literature and no plausible mechanistic link to the muscle calcium dysregulation underlying malignant hyperthermia. Evidence level is L5.
To proceed, the following is needed:
- Mechanism of action data and a documented mechanistic rationale linking sorbitol to ryanodine receptor or calcium handling
- Confirmation of the original indication, dosage form and approved indication for the UK authorisation
- Label-based warnings and contraindications from the SmPC and BNF
- Preclinical or mechanistic studies to support any plausible biological link
- Review of the Major interaction with tolevamer and the knowledge-graph peptic ulcer contraindication signal
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.